• Takeda posted FY2025 revenue of JPY 4.51 trillion, down 1.7%, while operating profit dropped 98.2% to JPY 6.2 billion.
• It turned to a net loss attributable to owners of JPY 152.4 billion; basic EPS was a loss of JPY 96.75.
• Other operating expenses widened to JPY 559 billion, driven by a JPY 403.5 billion provision tied to the AMITIZA antitrust verdict.
• It booked an additional legal provision of JPY 402.5 billion with related tax benefits of JPY 58.4 billion; the FY2025 year-end dividend stayed JPY 100.
• FY2026 forecast was unchanged, targeting revenue of JPY 4.64 trillion with operating profit of JPY 420 billion; dividend guidance remains JPY 204.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: CFNS2FME38R2NN35) on June 05, 2026, and is solely responsible for the information contained therein.